| Literature DB >> 36175947 |
Jerome Ateudjieu1,2,3, Ketina Hirma Tchio-Nighie4, Fernando Kemta Lekpa5,6, Ingrid Marcelle Koutio Douanla1, Frank Forex Kiadjieu Dieumo1, Paul Nyibio Ntsekendio1, Felicité Naah2, Cavin Epie Bekolo3, Anne Cecile Bisseck2,7.
Abstract
BACKGROUND: Researchers are responsible for the protection of health research participants. The purpose of this study was to identify and prioritize the training needs of researchers involved in human health research in Cameroon.Entities:
Keywords: Africa; Cameroon; Ethical evaluation; Health researchers; Research ethics; Research participants’ protection; Training needs
Mesh:
Year: 2022 PMID: 36175947 PMCID: PMC9523981 DOI: 10.1186/s12909-022-03767-z
Source DB: PubMed Journal: BMC Med Educ ISSN: 1472-6920 Impact factor: 3.263
Distribution of reached and consented health human researchers per region
| Region | Reached per region | Consented in each region | ||
|---|---|---|---|---|
| n | Proportion (%) | n | Proportion (%) | |
| Adamawa | 4 | 2.40 | 3 | 75.00 |
| Centre | 74 | 44.31 | 54 | 72.97 |
| East | 5 | 2.99 | 5 | 100.00 |
| Far North | 2 | 1.20 | 2 | 100.00 |
| Littoral | 24 | 14.37 | 19 | 79.17 |
| North | 10 | 5.99 | 7 | 70.00 |
| North West | 4 | 2.40 | 4 | 100.00 |
| West | 16 | 9.58 | 15 | 93.75 |
| South West | 28 | 16.77 | 25 | 89.29 |
| South | 0 | 00.00 | 0 | 00.00 |
| 80.24 | ||||
Main characteristics of human health researchers
| Characteristics | ||
|---|---|---|
| n | % | |
| Health Facilities | 29 | 21.64 |
| Researches institutes | 40 | 29.85 |
| Health training institutions | 65 | 48.51 |
| Female | 40 | 29.85 |
| Male | 94 | 70.15 |
| Biology | 41 | 30.60 |
| Medicine | 44 | 32.84 |
| Pharmacy | 7 | 5.22 |
| Public Health | 15 | 11.19 |
| Social Sciences | 6 | 4.48 |
| Statistics | 1 | 0.75 |
| Others | 20 | 14.93 |
aSome participants had more than one institution
Fig. 1Area of research of human health researchers
Exposure of participants to training in research ethics
| Themes on training received | ( | |
|---|---|---|
| n | % | |
| 72 | 53.73 | |
| 70 | 52.23 | |
| 64 | 47.76 | |
| 63 | 47.01 | |
| 62 | 46.27 | |
| 57 | 42.54 | |
| 54 | 40.30 | |
| 52 | 38.81 | |
| 51 | 38.06 | |
| 51 | 38.06 | |
| 50 | 37.31 | |
| 44 | 32.83 | |
| 41 | 30.59 | |
| 39 | 29.10 | |
| 8 | 5.97 | |
Coverage of related training among participant previously involved in trials studies
| Type of trials to which some participants have been involved | Frequency of participants claiming to have been involved: n/134(%) | Coverage of training on research participants’ protection in related trial: n (%) | Coverage of training in good clinical practices: n (%) |
|---|---|---|---|
| Clinical trials of drugs | 33(24.63) | 21(63.64) | 23(69.70) |
| Vaccine trials | 6(24.63) | 2(33.33) | 3(50.00) |
| Field trials | 38(24.63) | 20 (52.53) | 26(68.42) |
Fig. 2Source of previous training to which participants have been exposed
Exposure to regulations in research participant’s protection
| Guidelines | Known | Read | Used | |||
|---|---|---|---|---|---|---|
| Regulatory tests | n | % | n | % | n | % |
| 89 | 66.42 | 82 | 61.19 | 69 | 51.49 | |
| 70 | 52.24 | 57 | 42.54 | 42 | 31.34 | |
| 39 | 29.10 | 30 | 22.39 | 24 | 17.91 | |
| 34 | 25.37 | 29 | 21.64 | 24 | 17.91 | |
| 70 | 52.24 | 57 | 42.54 | 42 | 31.34 | |
| 39 | 29.10 | 30 | 22.39 | 24 | 17.91 | |
| 34 | 25.37 | 29 | 21.64 | 24 | 17.91 | |
Distribution of application to ethical clearance per main study focus designs of participants
| Study design | Frequency | Apply for ethical evaluation | ||
|---|---|---|---|---|
| n | % | n | % | |
| Analytical observational | 90 | 67.16 | 72 | 80.00 |
| Descriptive observational | 93 | 69.40 | 73 | 78.49 |
| Observational on databases | 42 | 31.34 | 32 | 76.19 |
| Qualitative study | 53 | 39.55 | 42 | 79.25 |
| Clinical trial on drugs | 33 | 24.63 | 29 | 87.88 |
| Clinical trial on vaccines | 6 | 4.48 | 4 | 66.67 |
| Clinical trial of medical devices | 12 | 8.96 | 11 | 91.67 |
| Clinical trials on Marketed Drugs | 15 | 11.19 | 13 | 86.67 |
| Laboratory Trials | 53 | 39.55 | 42 | 79.25 |
| Research on human biology | 34 | 25.37 | 24 | 70.59 |
| Research with transfer of biological material | 20 | 14.93 | 17 | 85.00 |
| Field Trial | 38 | 28.36 | 33 | 86.84 |
| Health services performance evaluation | 20 | 14.93 | 17 | 85.00 |
| Others | 11 | 8.21 | 9 | 81.82 |
Participants’ identified training needs
| Training area | ( | |
|---|---|---|
| n | % | |
| 72 | 53.73 | |
| 70 | 52.24 | |
| 64 | 47.76 | |
| 63 | 47.01 | |
| 62 | 46.27 | |
| 57 | 42.54 | |
| 54 | 40.30 | |
| 52 | 38.81 | |
| 51 | 38.06 | |
| 51 | 38.06 | |
| 50 | 37.31 | |
| 44 | 32.84 | |
| 41 | 30.60 | |
| 39 | 29.10 | |
| 8 | 5.97 | |
Researchers training needs priorities
| Ranking | Sum of Scores | Training needs |
|---|---|---|
| 1 | 87 | Guidelines and regulations on health research ethics and research participants protection in Cameroon |
| 2 | 63 | Procedures for evaluating research protocols |
| 3 | 59 | Protection of research participants in clinical trials |
| 4 | 40 | Fundamental ethical principles |
| 5 | 28 | Procedures for monitoring the implementation of research protocols |
| 6 | 18 | Drafting ethical consideration in a research protocol |
| 7 | 15 | Protection of research participants in field trials |
| 8 | 13 | Good Clinical Practices |
| 9 | 11 | Role of the investigator in protecting research participants |
| 10 | 7 | Planning and implementing Material Transfer Agreement on health research |
| 11 | 7 | Functioning of ethics committees |
| 12 | 3 | Obtaining informed consent |
| 13 | 3 | Bioethics and health research |
| 14 | 3 | Conducting Risk benefit ratio assessment |
| 15 | 3 | Community involvement in health research |
Fig. 3Sources of training most preferred